Gilead touts pivotal data for new kind of HIV therapy, opening towards large potential market

Pandemic aside, the last couple years at Gilead have been all about expansions: Moving beyond the HIV and hepatitis C antivirals that made them into a $77 billion company and into the immunology and oncology treatments that have become biotech’s bread and butter. Still, key HIV projects have continued as…

Click to view original post